Menu
Search
|

Menu

Close
X

Eli Lilly and Co LLY.N (New York Stock Exchange)

112.72 USD
+1.60 (+1.44%)
As of Sep 18
Previous Close 111.12
Open 111.55
Volume 823,132
3m Avg Volume 1,016,645
Today’s High 112.91
Today’s Low 111.17
52 Week High 132.12
52 Week Low 104.19
Shares Outstanding (mil) 970.83
Market Capitalization (mil) 105,548.70
Forward P/E 40.10
Dividend (Yield %) 0.64 ( 2.37 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.47 Mean rating from 15 analysts

KEY STATS

Revenue (mm, USD)
FY19
5,092
FY18
23,820
FY17
22,871
FY16
21,222
EPS (USD)
FY19
0.570
FY18
3.253
FY17
1.621
FY16
2.578
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
40.10
33.85
Price to Sales (TTM)
vs sector
4.41
7.90
Price to Book (MRQ)
vs sector
42.55
4.38
Price to Cash Flow (TTM)
vs sector
24.60
23.70
Total Debt to Equity (MRQ)
vs sector
643.68
17.64
LT Debt to Equity (MRQ)
vs sector
548.73
12.61
Return on Investment (TTM)
vs sector
9.26
12.69
Return on Equity (TTM)
vs sector
32.35
17.13

EXECUTIVE LEADERSHIP

David Ricks
Chairman of the Board, President, Chief Executive Officer, Since 2017
Salary: $1,400,000.00
Bonus: $3,633,000.00
Joshua Smiley
Chief Financial Officer, Senior Vice President, Since 2018
Salary: $875,000.00
Bonus: $1,438,060.00
Michael Harrington
Executive Vice President, General Counsel, Since 2019
Salary: $860,300.00
Bonus: $1,190,660.00
Aarti Shah
Senior Vice President - Chief Information and Digital Officer, Since 2018
Salary: --
Bonus: --
Daniel Skovronsky
Senior Vice President, Chief Scientific Officer, Since 2018
Salary: $837,500.00
Bonus: $1,376,430.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Lilly Corporate Ctr, Drop Code 1
INDIANAPOLIS   IN   46285

Phone: +1317.2762000

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

SPONSORED STORIES